Dynavax Technologies logo

Dynavax TechnologiesNASDAQ: DVAX

Profile

Sector:

Healthcare

Country:

United States

IPO:

19 February 2004

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A
$1.54 B
-38%vs. 3y high
78%vs. sector
107.09
-49%vs. 3y high
89%vs. sector
-93%vs. 3y high
63%vs. sector
-35%vs. 3y high
65%vs. sector

Price

after hours | Fri, 01 Nov 2024 21:16:25 GMT
$11.78+$0.08(+0.68%)

Dividend

No data over the past 3 years
$73.80 M$84.17 M
$73.80 M$11.39 M

Analysts recommendations

Institutional Ownership

DVAX Latest News

Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024
prnewswire.com24 October 2024 Sentiment: POSITIVE

EMERYVILLE, Calif. , Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close.

3 'Repeatable' Biotech Trades
seekingalpha.com25 September 2024 Sentiment: POSITIVE

Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.

Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
seekingalpha.com23 August 2024 Sentiment: NEUTRAL

Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sidelined. Supported by ample liquidity, Dynavax is evaluating business development on a disciplined basis.

How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98%
zacks.com09 August 2024 Sentiment: POSITIVE

The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
zacks.com06 August 2024 Sentiment: POSITIVE

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.

Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
prnewswire.com23 July 2024 Sentiment: POSITIVE

EMERYVILLE, Calif. , July 23, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the U.S. financial markets close.

Dynavax to Present at Upcoming Investor Conferences
prnewswire.com28 May 2024 Sentiment: POSITIVE

EMERYVILLE, Calif. , May 28, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will present at the following upcoming investor conferences during the month of June: William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 1:20 p.m.

US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine
Reuters14 May 2024 Sentiment: NEGATIVE

The FDA has rejected Dynavax Technologies' request to expand the use of their hepatitis B vaccine for hemodialysis patients, according to the company's announcement on Tuesday.

Dynavax Technologies: Still A Believer
Seeking Alpha24 March 2024 Sentiment: POSITIVE

Dynavax's core asset, HEPISLAV-B, saw a 69% increase in sales in FY23, making the company cash flow positive. The company's CpG 1018 vaccine candidates are advancing in mid-stage trials, with Heplisav potential sales reaching $400 million by FY27. Dynavax's stock has been trading at the lower end of its range, but with positive prospects and a strong balance sheet, it presents a solid long-term investment opportunity.

Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript
Seeking Alpha22 February 2024 Sentiment: POSITIVE

Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript

  • 1(current)

What type of business is Dynavax Technologies?

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

What sector is Dynavax Technologies in?

Dynavax Technologies is in the Healthcare sector

What industry is Dynavax Technologies in?

Dynavax Technologies is in the Drug Manufacturers - Specialty & Generic industry

What country is Dynavax Technologies from?

Dynavax Technologies is headquartered in United States

When did Dynavax Technologies go public?

Dynavax Technologies initial public offering (IPO) was on 19 February 2004

What is Dynavax Technologies website?

https://www.dynavax.com

Is Dynavax Technologies in the S&P 500?

No, Dynavax Technologies is not included in the S&P 500 index

Is Dynavax Technologies in the NASDAQ 100?

No, Dynavax Technologies is not included in the NASDAQ 100 index

Is Dynavax Technologies in the Dow Jones?

No, Dynavax Technologies is not included in the Dow Jones index

When was Dynavax Technologies the previous earnings report?

No data

When does Dynavax Technologies earnings report?

Next earnings report date is not announced yet